Related Experiment Video
Updated: Sep 27, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
A phase I study of continuous administration of 5-fluorouracil/cisplatin in advanced uterine cervical cancer
Yoshio Yoshida1, Kenji Goto, Kazumi Kawahara
1Department of Obstetrics and Gynecology, Fukui Medical University, Matsuoka-Cho, Yoshida-Gum, Fukui 910-1193, Japan. yyoshida@fmsrsa.fukui-med.ac.ip
Background:
The aim of this study was to assess the toxicity of a neoadjuvant chemotherapy (NAC) regimen consisting of cisplatin (CDDP) and 5-fluorouracil (5-FU) through 24-hour intravenous continuous infusion on days 1-4 in a Phase I study.
Patients And Methods:
Thirteen patients were recruited for this study. All patients were treated with a regimen consisting of CDDP and 5-FU through a 24-hour intravenous continuous infusion on days 1-4, followed by radical hysterectomy and/or radiation. Each initial dose of CDDP and 5-FU was 20 mg/m2/day and 750 mg/m2/day, respectively, for 4 days.
Results And Conclusion:
In the third step, seven patients were treated at 25 mg/m2 day CDDP and 1000 mg/m2/day 5-FU, respectively, for 4 days. One of seven patients showed Grade 4 thrombopenia. However, in this dose step, all the patients showed an objective response. Although maximum tolerated doses (MTDs) were not reached, we decided to stop the escalation and to recommend this level for the Phase II study.
